Alcon’s latest snapshot: Swiss‑based eye‑care firm trades near CHF 56, below its 200‑day SMA yet well above its 52‑week low, with a 4% monthly rise and a 3‑5% upside forecast driven by AI‑powered cataract tech, global expansion, and disciplined cost…